@article{67699fb1cce64eca9c26561ccbaff770,
title = "Gastrointestinal Eosinophil Responses in a Longitudinal, Randomized Trial of Peanut Oral Immunotherapy",
abstract = "Background & Aims: Gastrointestinal side effects are common during oral immunotherapy (OIT) and eosinophilic esophagitis (EoE) is a potential complication. We aimed to characterize eosinophilic gastrointestinal responses to peanut OIT, in which peanut protein is given orally, with incremental increases in dose over time. Methods: Twenty adults with IgE-mediated peanut allergy were randomly assigned to groups given peanut OIT (n = 15) or placebo (n = 5); 1 additional subject withdrew before randomization. Serial gastrointestinal biopsies were collected at baseline (n = 21, 0 weeks), following dose escalation (n = 10, 52 weeks), and during the maintenance phase (n = 11, 104 weeks). Endoscopic findings were characterized using the EoE endoscopic reference score. Biopsies were assessed for eosinophils per high-power field (eos/hpf) and other pathology features using EoE histologic scoring system scores. We performed immunohistochemical analyses of eosinophil peroxidase deposition, quantified using automated image analysis. Results: At baseline, no subjects reported current gastrointestinal symptoms. However, 3 of the 21 subjects (14%) had esophageal peak eosinophil counts ≥15 eos/hpf and all subjects had dilated intercellular spaces (DIS). OIT induced or exacerbated esophageal eosinophilia (EE) at 52 weeks in most subjects (peak eosinophil counts >5 eos/hpf in 6 of 7 patients [86%]; peak eosinophil counts ≥15 eos/hpf in 4 of 7 patients [57%]). One subject met clinicopathologic criteria for EoE and withdrew; no significant changes in esophageal peak eosinophil counts were observed in the placebo group. EE in the OIT group corresponded with significant increases in EoE histologic scoring system scores and deposition of eosinophil peroxidase. In 4 of 6 participants (67%), OIT-induced EE and gastrointestinal eosinophilia resolved by the end of the maintenance phase. Gastrointestinal symptoms were not clearly associated with EE or gastrointestinal eosinophilia. Conclusions: In this pilot study, we found that peanut OIT-induced EE and gastrointestinal eosinophilia are usually transient and are not always associated with gastrointestinal symptoms. Clinicaltrials.gov",
keywords = "EREFS, EoEHSS, Food Allergy, Inflammation",
author = "Wright, {Benjamin L.} and Fernandez-Becker, {Nielsen Q.} and Neeraja Kambham and Natasha Purington and Shu Cao and Dana Tupa and Wenming Zhang and Sindher, {Sayantani B.} and Rank, {Matthew A.} and Hirohito Kita and Katzka, {David A.} and Shim, {Kelly P.} and Bunning, {Bryan J.} and Doyle, {Alfred D.} and Jacobsen, {Elizabeth A.} and Mindy Tsai and Boyd, {Scott D.} and Monali Manohar and Chinthrajah, {R. Sharon}",
note = "Funding Information: Funding Supported by NIH grant U19Al104209, Donald and Kathy Levin Family Foundation, Mayo Clinic Foundation, and the Sean N. Parker Center for Allergy and Asthma Research at Stanford University.The authors thank the patients who participated in this study. The authors also acknowledge Stephen Galli, MD, PhD, Holden Maecker, PhD, James J. Lee, PhD, and Kari Nadeau, MD, PhD for their contributions to the study and to the manuscript. The authors thank Vanitha Sampath, who provided editorial assistance as a medical writer funded by Stanford University. Benjamin L. Wright, MD (Formal analysis: Lead; Funding acquisition: Supporting; Investigation: Equal; Methodology: Equal; Project administration: Lead; Resources: Supporting; Supervision: Equal; Writing ? original draft: Lead; Writing ? review & editing: Equal), Nielsen Q. Fernandez-Becker, MD, PhD (Investigation: Equal; Methodology: Supporting; Writing ? review & editing: Supporting), Neeraja Kambham, MD (Formal analysis: Supporting; Investigation: Equal; Methodology: Equal; Writing ? review & editing: Supporting), Natasha Purington, MS (Data curation: Equal; Formal analysis: Lead; Writing ? review & editing: Supporting), Shu Cao, MS (Data curation: Equal; Formal analysis: Lead; Writing ? review & editing: Equal), Dana Tupa, MS (Data curation: Equal; Writing ? review & editing: Supporting), Wenming Zhang, PhD (Investigation: Equal; Writing ? review & editing: Supporting), Sayantani Sindher, MD (Conceptualization: Supporting; Investigation: Supporting), Matthew A. Rank, MD (Formal analysis: Supporting; Investigation: Supporting; Resources: Supporting; Writing ? review & editing: Supporting), Hirohito Kita, MD (Supervision: Supporting; Writing ? review & editing: Supporting), David A. Katzka, MD (Methodology: Supporting; Writing ? review & editing: Supporting), Kelly P. Shim, BS (Investigation: Equal; Writing ? review & editing: Supporting), Bryan J. Bunning, BS (Investigation: Supporting; Writing ? review & editing: Supporting), Alfred D. Doyle, PhD (Investigation: Supporting; Writing ? review & editing: Supporting), Elizabeth A. Jacobsen, PhD (Resources: Supporting; Writing ? review & editing: Supporting), Mindy Tsai, DMSc (Investigation: Supporting; Writing ? review & editing: Supporting), Scott D. Boyd, MD, PhD (Investigation: Supporting; Writing ? review & editing: Supporting), Monali Manohar, PhD (Investigation: Supporting; Writing ? review & editing: Supporting), R. Sharon Chinthrajah, MD (Conceptualization: Lead; Formal analysis: Equal; Funding acquisition: Lead; Investigation: Lead; Methodology: Equal; Supervision: Lead; Writing ? original draft: Equal; Writing ? review & editing: Lead) Funding Information: Funding Supported by NIH grant U19Al104209 , Donald and Kathy Levin Family Foundation, Mayo Clinic Foundation , and the Sean N. Parker Center for Allergy and Asthma Research at Stanford University . Funding Information: Conflicts of interest These authors disclose the following: BLW reports grants from Arizona Biomedical Research Commission and Phoenix Children{\textquoteright}s Hospital Foundation. SDB reports grants from NIH (U19AI104209 and R01AI125567) during the conduct of the study and personal fees from Regeneron/Sanofi outside the submitted work. SBS reports grant support from NIH and is involved in clinical trials with Regeneron, Aimmune Therapeutics, DBV Technologies, Adare Pharmaceuticals, Sanofi, and Novartis. RSC is a consultant for Alladapt and reports grants from NIAID, CoFAR, Aimmune Therapeutics, DBV Technologies, Astellas, AnaptysBio, Novartis, and Regeneron. The remaining authors disclose no conflicts. Publisher Copyright: {\textcopyright} 2021 AGA Institute",
year = "2021",
month = jun,
doi = "10.1016/j.cgh.2020.05.019",
language = "English (US)",
volume = "19",
pages = "1151--1159.e14",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "6",
}